

27th February, 2024

BSE Limited

P.J. Towers, Dalal Street, Fort, Mumbai- 400 001 BSE scrip code: 543635

National Stock Exchange of India Limited

Exchange Plaza, Bandra-Kurla Complex, Bandra (East), Mumbai – 400 051 NSE symbol: PPLPHARMA

Sub: Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ('SEBI Listing Regulations')

Dear Sir / Madam,

Pursuant to Regulation 30 of the SEBI Listing Regulations, we hereby inform you regarding a fine of Euros 182,001 imposed on Piramal Critical Care B.V. ('PCC BV'), a step-down wholly owned subsidiary of the Company by the Audiencia Nacional, Spain on 26th February, 2024 ('Audiencia').

PCC BV received a sanction letter in April 2021 from Spanish Agency of Medicines and Medical Devices ('AEMPS') for non-supply of a product in Spain for a brief period from 22nd May, 2019 till 18th June 2019, which coincided with the transfer of the Marketing Authorization in Spain from Janssen Pharma S.L. to PCC BV (i.e. 22nd May, 2019). The sanction was not issued for technical or quality reasons but was instead based on an alleged insufficient supply of stock to the market. In this connection, on an appeal by PCC BV, Audiencia, the appellate judicial body, passed an order upholding a fine of Euros 182,001 (inclusive of court fee).

PCC BV is contemplating filing an appeal against the Audiencia's judgment before the Supreme Court in Spain.

The fine levied on PCC BV, does not have any material impact on financials, operations, or other activities of the Company.

Kindly take above on record and oblige.

Thank you,

Yours truly,

For Piramal Pharma Limited

Tanya Sanish Company Secretary